Skip to main content

Myositis

In case you missed it…a popular read. Clinical Associations with Myositis Antibodies Read the full article on #RheumNow https://t.co/tzPU1scc8x https://t.co/pmmtmIuz31
Dr. John Cush @RheumNow( View Tweet )
Oct 16, 2021
Clinical Associations with Myositis Antibodies Read the full post on #RheumNow https://t.co/tzPU1scc8x https://t.co/F537tPAQTU
Dr. John Cush @RheumNow( View Tweet )
Oct 11, 2021

Clinical Associations with Myositis Antibodies

Oct 07, 2021

While myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) may have prognostic value through their clinical associations, many patients will not have them and overall, they are poorly predictive of a malignancy risk. 

Read Article
ICYMI: JAK inhibitors as potential treatment for Juvenile Dermatomyositis: nice review of the biology of JAKi effects and the reports of JAKi success in adults and kids with IIM https://t.co/k3qunsCdBN https://t.co/nyqMo6vh88
Dr. John Cush @RheumNow( View Tweet )
Oct 03, 2021

RheumNow Podcast – Jack of All Subspecialties (10.1.2021)

Oct 01, 2021

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com




  1. A population based Swedish study of birth records shows that antibiotic exposure in first three years of life to be associated with a future risk of JIA, although infections during fetal

Read Article

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Sep 23, 2021

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID

Read Article

High Comorbidity Rates with Inclusion Body Myositis

Sep 21, 2021

Inclusion body myositis (IBM) patients tend to be older than those with idiopathic inflammatory myositis (IIM), but the scope of disease beyond their myositis is not appreciated. Now, a population-based, case-control study suggests both a lower overall survival and high comorbidity burden in

Read Article

Pneumocystis Often Lethal in Dermatomyositis

MedPage Today
Sep 14, 2021

Patients with dermatomyositis who were positive for a myositis-specific antibody had a much higher incidence of and mortality associated with Pneumocystis jirovecii infection than patients with other antibody-negative idiopathic inflammatory myopathies, Chinese researchers found.

Read Article
J Hopkins study of 524 myositis-specific Ab positive pts shows that while 91% met 2017 EULAR/ACR criteria for Dx of myositis, 20% of HMGCR+ & 50% anti-PL7 did not classify as myositis; ~10% anti-SRP & HMGCR were dx as inclusion body myositis https://t.co/jcIn6SzbGG

Dr. John Cush @RheumNow( View Tweet )

Sep 10, 2021

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

Sep 10, 2021

This week: high science that affect future treatments; breakthrough infections in our patients, and what's up with that; and soon your radiologist is going to be replaced by AI. This and more in our review of the news and journal articles from the past week.

Read Article
Differential Dx of immune-mediated necrotizing myopathies (IMNM) - HMGCR & Signal recognition particle Abs; checkpoint inhibitors, anti-Mi2 dermatomyositis, antisynthetase syndr. antimitochondrial Abs, GVHD, SARS-CoV-2 infection https://t.co/hhizx5gAet

Dr. John Cush @RheumNow( View Tweet )

Sep 10, 2021
Popular on RheumNow https://t.co/BZsl8a6ArW The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/RNFsJadUZx
Dr. John Cush @RheumNow( View Tweet )
Aug 16, 2021
ICYMI: Skin Involvement with HMGCR Necrotizing Myositis The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, more so than previously reported. https://t.co/RR07dYIJSr https://t.co/MiaIqvMPaB
Dr. John Cush @RheumNow( View Tweet )
Aug 08, 2021

Skin Involvement with HMGCR Necrotizing Myositis

Aug 04, 2021

The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, moreso than previously reported.



Anti-3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies have been linked to the immune-mediated

Read Article
204 pts w/ dermatomyositis/polymyositis Rx w/ IV early pulse steroids(IVMP) or IVIG. IVMP & IVMP+IVIG was assoc w/ 56-58% incr odds of complete response. Pulse IVMP+IVIG incr risk of steroid D/C. Early IVMP/IVIG=no impact on mortality https://t.co/yRFJgos8Qq

Dr. John Cush @RheumNow( View Tweet )

Jul 28, 2021
ICYMI: FDA Approves IVIG in Dermatomyositis https://t.co/BZsl8a6ArW The FDA has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/VFF0QMqbin
Dr. John Cush @RheumNow( View Tweet )
Jul 24, 2021

FDA Approves IVIG in Dermatomyositis

Jul 20, 2021

The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM).



The manufacturer, Octapharma USA, received

Read Article
Septic arthritis MIMICs (all presenting as acute monoarthritis) - consider: cellulitis, bursitis, abscess, osteonecrosis, gout, pseudogout, Lyme, Osteomyelitis, reactive arthritis, Lyme disease,, Rheumatoid arthritis, & Transient synovitis (kids) https://t.co/uNirAcoBds

Dr. John Cush @RheumNow( View Tweet )

Jul 10, 2021

ICYMI: 2020 Rheumatology Year in Review

Jul 08, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article
ProDERM Study: IVIG in Dermatomyositis--The ProDERM study show that IVIg is safe, effective and superior to placebo in patients with dermatomyositis (DM). https://t.co/HOB8CYn9yc https://t.co/4nNRRhzHVO
Dr. John Cush @RheumNow( View Tweet )
Jul 06, 2021
ProDERM OP0008: IVIG 2g/kg q4w for dermatomyositis vs PBO, open-label extension. TIS score responders 78% vs 43%. IVIG great option: Not immunosuppressive and works fast, watch for headache, pyrexia, nausea, risk of VTE. #EULAR2021 @RheumNow https://t.co/m4CEkg3EyC
Eric Dein @ejdein1( View Tweet )
Jun 02, 2021
ProDERM study (95 pts): RBPCT phase III IVIG 10% is effective in dermatomyositis (2 g/kg over 2-5 days q4 weeks. (common AEs: HA, fever, nausea most common AEs, rare SAE include thrombosis, LoC, hypoesthesia). Dr. R Aggarwal Abstr#OP008 #EULAR2021 @RheumNow https://t.co/ScTdUySxOl
Jun 02, 2021

RheumNow Podcast – BandAids for Rheumatologists (5.14.2021)

May 14, 2021

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com - a website for rheumatologists, by rheumatologists.



We love Rheumatology!




  1. CDC study from 33 sites, 25 states showed vaccine efficacy (against Sx COVID) in HCP was 82% with ONEdose

Read Article

New, Improved Therapy for Pompe Disease

Apr 16, 2021

Researchers from the University of Cincinnati Gardner Neuroscience Institute will present data on a new treatment for Pompe disease at the American Academy of Neurology on April 20th; the results show that treatment with avalglucosidase alfa yielded substantial clinical improvements and a more

Read Article

RheumNow Podcast – Combination Biologics

Apr 16, 2021

Dr. Jack Cush serves up this week's news and articles from RheumNow.com.

Read Article
×